Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
Aliso Viejo, CA, September 1, 2009 - Ambry Genetics announced today that they have completed certification to become an Agilent Certified Service Provider on the Agilent MicroArray platform. The initial certification is for Comparative Genomic Hybridization (aCGH) which is an application used by researchers to discover and detect genomic copy number variations within specific genomes.
The Agilent Certified Service Provider program comprises a select list of strategic organizations that pass a rigorous assessment to use Agilent's MicroArray platform. The program combines the provider's focused expertise with the complete Agilent MicroArray workflow to create specialized services or complete genomic research solutions.
"We are thrilled to be the first Agilent Certified Service Provider on the West Coast of the United States," said Ardy Arianpour, Director of Business Development, Pharmaceutical Services at Ambry Genetics. "Our Pharmaceutical, Biotech, and Academic customers will be able to receive the highest quality results and service with the CSP stamp of approval. This accomplishment continues to demonstrate Ambry Genetics’ dedication to our customers and the genomics services industry."
"Array comparative genomic hybridization has become the approach of choice in research settings to comprehensively identify chromosomal imbalances throughout the genome," added Dr. Aaron Elliott, R&D Scientist, Ambry Genetics. "Agilent’s wide variety of catalog arrays combined with a cost effective custom design capability available through Agilent’s eArray Software allows us to provide our researchers with highly sensitive genome-wide scans at varying resolutions. Our CSP status further ensures our researchers that they are getting the best quality service available."
For more information about Ambry Genetics research support MicroArray services click here.
Agilent Technologies, Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 18,000 employees serve customers in more than 110 countries. Agilent had net revenues of $5.8 billion in fiscal 2008. Information about Agilent Technologies, Inc. is available on the Web at www.agilent.com.
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com